Through collaboration with the Medical Research Council and the Agricultural Research Council in Cape Town, South Africa we have identified a number of botanicals having beneficial physiological effects.

In particular we have worked with certain extracts of such botanicals that assist in the maintenance of normal blood glucose levels and possibly reduce risk factor(s) for the development of diabetes.
We are developing these botanicals as foods with health claims and aim to partner with leading companies in this field. More information.

Through characterization and analysis of plant extracts we have also identified RX-1 which is a small molecule having significant anti-diabetic activity as demonstrated in our

pre-clinical studies in various  animal models, presumably through a novel mode of action.
We are developing RX-1 as a drug and our strategy is to conduct key preclinical studies ourselves and then partner up with a leading diabetes company for further development.

More information

Our oral anti-diabetic projects are managed in a lean organization in collaboration with research institutions, CRO's and our Senior Scientific Advisor in Diabetes, Prof. Jørn Nerup.